Peter J Little,, Bpharm

List of Publications by Year in Descending Order

210 papers	6,366 citations	44 h-index	68 g-index
216 ext. papers	7,452 ext. citations	5.9 avg, IF	5.98 L-index

#	Paper	IF	Citations
210	Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.. *Acta Pharmacologica Sinica*, **2022**,	8	4
209	Lipopolysaccharide acting via toll-like receptor 4 transactivates the TGF-receptor in vascular smooth muscle cells.. *Cellular and Molecular Life Sciences*, **2022**, 79, 121	10.3	1
208	Endothelin-1 mediated glycosaminoglycan synthesizing gene expression involves NOX-dependent transactivation of the transforming growth factor-receptor.. *Molecular and Cellular Biochemistry*, **2022**, 1	4.2	0
207	Pharmacological Inhibition of IRAK1 and IRAK4 Prevents Endothelial Inflammation and Atherosclerosis in ApoE Mice.. *Pharmacological Research*, **2021**, 175, 106043	10.2	0
206	Akt acts as a switch for GPCR transactivation of the TGF-receptor type 1. *FEBS Journal*, **2021**,	5.7	1
205	Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. *Theranostics*, **2021**, 11, 9376-9396	12.1	6
204	Curcumin Inhibits Lysophosphatidic Acid Mediated MCP-1 Expression via Blocking ROCK Signalling. *Molecules*, **2021**, 26,	4.8	6
203	Poly(aspartic acid) in Biomedical Applications: From Polymerization, Modification, Properties, Degradation, and Biocompatibility to Applications. *ACS Biomaterials Science and Engineering*, **2021**, 7, 2083-2105	5.5	13
202	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. *Pharmacological Reviews*, **2021**, 73, 924-967	22.5	73
201	Metformin, Macrophage Dysfunction and Atherosclerosis. *Frontiers in Immunology*, **2021**, 12, 682853	8.4	10
200	Endothelial Dysfunction and Cardiovascular Disease: History and Analysis of the Clinical Utility of the Relationship. *Biomedicines*, **2021**, 9,	4.8	12
199	YY-11, a camel milk-derived peptide, inhibits TGF-mediated atherogenic signaling in human vascular smooth muscle cells. *Journal of Food Biochemistry*, **2021**, e13882	3.3	
198	Emodin in atherosclerosis prevention: Pharmacological actions and therapeutic potential. *European Journal of Pharmacology*, **2021**, 890, 173617	5.3	9
197	Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 601-613	9.4	21
196	Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. *Theranostics*, **2021**, 11, 4502-4515	12.1	16
195	The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction. *Signal Transduction and Targeted Therapy*, **2021**, 6, 266	21	10
194	The role of FOXOs and autophagy in cancer and metastasis-Implications in therapeutic development. *Medicinal Research Reviews*, **2020**, 40, 2089-2113	14.4	9

193	Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function. *Frontiers in Pharmacology*, **2020**, 11, 635	5.6	14
192	Toll-like Receptor 4 Stimulates Gene Expression via Smad2 Linker Region Phosphorylation in Vascular Smooth Muscle Cells. *ACS Pharmacology and Translational Science*, **2020**, 3, 524-534	5.9	6
191	The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease. *ACS Pharmacology and Translational Science*, **2020**, 3, 457-471	5.9	12
190	Smad2 linker region phosphorylation is an autonomous cell signalling pathway: Implications for multiple disease pathologies. *Biomedicine and Pharmacotherapy*, **2020**, 124, 109854	7.5	9
189	Vernolide-A and Vernodaline: Sesquiterpene Lactones with Cytotoxicity against Cancer. *Journal of Environmental Pathology, Toxicology and Oncology*, **2020**, 39, 299-308	2.1	2
188	Hydrogels as artificial matrices for cell seeding in microfluidic devices.. *RSC Advances*, **2020**, 10, 43682-43703	3.7	23
187	ROS directly activates transforming growth factor β type 1 receptor signalling in human vascular smooth muscle cells. *Biochimica Et Biophysica Acta - General Subjects*, **2020**, 1864, 129463	4	11
186	Naringenin and naringin in cardiovascular disease prevention: A preclinical review. *European Journal of Pharmacology*, **2020**, 887, 173535	5.3	36
185	Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells. *Biochemical and Biophysical Research Communications*, **2020**, 532, 239-243	3.4	
184	Lysophosphatidic acid receptor 5 transactivation of TGFBR1 stimulates the mRNA expression of proteoglycan synthesizing genes XYLT1 and CHST3. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118848	4.9	8
183	Glutamate Attenuates the Survival Property of IGFR through NR2B Containing N-Methyl-D-aspartate Receptors in Cortical Neurons. *Oxidative Medicine and Cellular Longevity*, **2020**, 2020, 5173184	6.7	1
182	Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-β signalling. *Cellular and Molecular Life Sciences*, **2020**, 77, 243-251	10.3	14
181	Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease. *Pharmacology & Therapeutics*, **2019**, 204, 107404	13.9	16
180	Treatment of atherosclerotic plaque: perspectives on theranostics. *Journal of Pharmacy and Pharmacology*, **2019**, 71, 1029-1043	4.8	38
179	Non-invasive imaging techniques for the differentiation of acute and chronic thrombosis. *Thrombosis Research*, **2019**, 177, 161-171	8.2	22
178	Endothelin-1 increases CHSY-1 expression in aortic endothelial cells via transactivation of transforming growth factor β type I receptor induced by type B receptor endothelin-1. *Journal of Pharmacy and Pharmacology*, **2019**, 71, 988-995	4.8	4
177	Targeting Mechanosensitive Transcription Factors in Atherosclerosis. *Trends in Pharmacological Sciences*, **2019**, 40, 253-266	13.2	66
176	Role of Corticotropin Releasing Factor in the Neuroimmune Mechanisms of Depression: Examination of Current Pharmaceutical and Herbal Therapies. *Frontiers in Cellular Neuroscience*, **2019**, 13, 290	6.1	12

175	Mechanisms of PAR-1 mediated kinase receptor transactivation: Smad linker region phosphorylation. *Journal of Cell Communication and Signaling*, **2019**, 13, 539-548	5.2	13
174	Hydrogels Based on Poly(aspartic acid): Synthesis and Applications. *Frontiers in Chemistry*, **2019**, 7, 755	5	13
173	GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species. *Vascular Biology (Bristol, England)*, **2019**, 1, R1-R11	2.9	6
172	Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential. *Pharmacological Research*, **2019**, 139, 62-75	10.2	51
171	Transforming growth factor-β1 mediated CHST11 and CHSY1 mRNA expression is ROS dependent in vascular smooth muscle cells. *Journal of Cell Communication and Signaling*, **2019**, 13, 225-233	5.2	20
170	Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. *Pharmacology & Therapeutics*, **2019**, 196, 15-43	13.9	66
169	Individual Smad2 linker region phosphorylation sites determine the expression of proteoglycan and glycosaminoglycan synthesizing genes. *Cellular Signalling*, **2019**, 53, 365-373	4.9	17
168	Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. *Annals of the New York Academy of Sciences*, **2019**, 1443, 34-53	6.5	44
167	Forkhead box protein O3 suppresses uveal melanoma development by increasing the expression of Bcl-2-like protein 11 and cyclin-dependent kinase inhibitor 1B. *Molecular Medicine Reports*, **2018**, 17, 3109-3114	2.9	4
166	Signalling pathways regulating galactosaminoglycan synthesis and structure in vascular smooth muscle: Implications for lipoprotein binding and atherosclerosis. *Pharmacology & Therapeutics*, **2018**, 187, 88-97	13.9	23
165	Changing environment of hyperglycemia in pregnancy: Gestational diabetes and diabetes mellitus in pregnancy. *Journal of Diabetes*, **2018**, 10, 633-640	3.8	10
164	Flavopiridol Inhibits TGF--Stimulated Biglycan Synthesis by Blocking Linker Region Phosphorylation and Nuclear Translocation of Smad2. *Journal of Pharmacology and Experimental Therapeutics*, **2018**, 365, 156-164	4.7	20
163	Thrombin promotes PAI-1 expression and migration in keratinocytes via ERK dependent Smad linker region phosphorylation. *Cellular Signalling*, **2018**, 47, 37-43	4.9	22
162	G protein coupled receptors can transduce signals through carboxy terminal and linker region phosphorylation of Smad transcription factors. *Life Sciences*, **2018**, 199, 10-15	6.8	14
161	Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen. *Medicinal Research Reviews*, **2018**, 38, 201-228	14.4	62
160	IGF-1-Mediated Survival from Induced Death of Human Primary Cultured Retinal Pigment Epithelial Cells Is Mediated by an Akt-Dependent Signaling Pathway. *Molecular Neurobiology*, **2018**, 55, 1915-1927	6.2	8
159	Endothelial function and dysfunction: Impact of metformin. *Pharmacology & Therapeutics*, **2018**, 192, 150-162	13.9	59
158	Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis. *Nanoscale*, **2018**, 10, 15103-15115	7.7	32

157	Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. *Theranostics*, **2018**, 8, 3007-3021	12.1	33
156	Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	14
155	Novel iron oxide-cerium oxide core-shell nanoparticles as a potential theranostic material for ROS related inflammatory diseases. *Journal of Materials Chemistry B*, **2018**, 6, 4937-4951	7.3	46
154	The Atypical Antipsychotic Agent, Clozapine, Protects Against Corticosterone-Induced Death of PC12 Cells by Regulating the Akt/FoxO3a Signaling Pathway. *Molecular Neurobiology*, **2017**, 54, 3395-3406	6.2	24
153	The emerging role of metformin in gestational diabetes mellitus. *Diabetes, Obesity and Metabolism*, **2017**, 19, 765-772	6.7	23
152	Insights into cellular signalling by G protein coupled receptor transactivation of cell surface protein kinase receptors. *Journal of Cell Communication and Signaling*, **2017**, 11, 117-125	5.2	18
151	Role of brain-derived neurotrophic factor and nerve growth factor in the regulation of Neuropeptide W in vitro and in vivo. *Molecular and Cellular Endocrinology*, **2017**, 447, 71-78	4.4	9
150	Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes. *Biomedicine and Pharmacotherapy*, **2017**, 89, 1242-1251	7.5	38
149	RNA sequencing to determine the contribution of kinase receptor transactivation to G protein coupled receptor signalling in vascular smooth muscle cells. *PLoS ONE*, **2017**, 12, e0180842	3.7	12
148	Amiodarone-Induced Retinal Neuronal Cell Apoptosis Attenuated by IGF-1 via Counter Regulation of the PI3k/Akt/FoxO3a Pathway. *Molecular Neurobiology*, **2017**, 54, 6931-6943	6.2	18
147	Ga proteins: molecular pharmacology and therapeutic potential. *Cellular and Molecular Life Sciences* , **2017**, 74, 1379-1390	10.3	27
146	FOXO Signaling Pathways as Therapeutic Targets in Cancer. *International Journal of Biological Sciences*, **2017**, 13, 815-827	11.2	198
145	Endothelin-1 (ET-1) stimulates carboxy terminal Smad2 phosphorylation in vascular endothelial cells by a mechanism dependent on ET receptors and de novo protein synthesis. *Journal of Pharmacy and Pharmacology*, **2017**, 69, 66-72	4.8	16
144	Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells. *Biomedicine and Pharmacotherapy*, **2016**, 84, 1538-1550	7.5	20
143	Multidisciplinary involvement in completion of a hospital medication management plan in a tertiary hospital in australia. *Journal of Pharmacy Practice and Research*, **2016**, 46, 192-194	0.7	
142	Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response. *Journal of Pharmacy and Pharmacology*, **2016**, 68, 368-78	4.8	7
141	Lithium ions attenuate serum-deprivation-induced apoptosis in PC12 cells through regulation of the Akt/FoxO1 signaling pathways. *Psychopharmacology*, **2016**, 233, 785-94	4.7	18
140	Protease activated receptor-1 mediated dual kinase receptor transactivation stimulates the expression of glycosaminoglycan synthesizing genes. *Cellular Signalling*, **2016**, 28, 110-9	4.9	30

139	Cellular and Molecular Pathology of Age-Related Macular Degeneration: Potential Role for Proteoglycans. *Journal of Ophthalmology*, **2016**, 2016, 2913612	2	21
138	An Investigation of Sodium Fusidate and Recombinant Cytochrome P450 Enzymes Inhibition In-Vitro. *Drug Metabolism Letters*, **2016**, 10, 180-186	2.1	1
137	Multiple Growth Factors, But Not VEGF, Stimulate Glycosaminoglycan Hyperelongation in Retinal Choroidal Endothelial Cells. *International Journal of Biological Sciences*, **2016**, 12, 1041-51	11.2	4
136	SIRT6 protects against endothelial dysfunction and atherosclerosis in mice. *Aging*, **2016**, 8, 1064-82	5.6	60
135	Integrating the GPCR transactivation-dependent and biased signalling paradigms in the context of PAR1 signalling. *British Journal of Pharmacology*, **2016**, 173, 2992-3000	8.6	11
134	The role of specific Smad linker region phosphorylation in TGF-□mediated expression of glycosaminoglycan synthesizing enzymes in vascular smooth muscle. *Cellular Signalling*, **2016**, 28, 956-66	4.9	35
133	IGF-1 signaling via the PI3K/Akt pathway confers neuroprotection in human retinal pigment epithelial cells exposed to sodium nitroprusside insult. *Journal of Molecular Neuroscience*, **2015**, 55, 931-40	2.3	24
132	The expansion of GPCR transactivation-dependent signalling to include serine/threonine kinase receptors represents a new cell signalling frontier. *Cellular and Molecular Life Sciences*, **2015**, 72, 799-808	10.3	30
131	Determination of dose enhancement caused by gold-nanoparticles irradiated with proton, X-rays (kV and MV) and electron beams, using alanine/EPR dosimeters. *Radiation Measurements*, **2015**, 82, 122-128	1.5	17
130	Peptidyl-prolyl isomerases: functionality and potential therapeutic targets in cardiovascular disease. *Clinical and Experimental Pharmacology and Physiology*, **2015**, 42, 117-24	3	15
129	The status of radioimmunotherapy in CD20+ non-Hodgkin□s lymphoma. *Targeted Oncology*, **2015**, 10, 15-26	5	12
128	Methotrexate Inhibits Proliferation but not Proteoglycan Synthesis or Glycosaminoglycan Hyperelongation in Human Vascular Smooth Muscle Cells. *Clinical & Experimental Pharmacology*, **2015**, 05,	1	1
127	Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, G□q,11. *Frontiers in Cardiovascular Medicine*, **2015**, 2, 14	5.4	31
126	Nerve growth factor protects retinal ganglion cells against injury induced by retinal ischemia-reperfusion in rats. *Growth Factors*, **2015**, 33, 149-59	1.6	18
125	Forkhead box O transcription factors as possible mediators in the development of major depression. *Neuropharmacology*, **2015**, 99, 527-37	5.5	33
124	Total synthesis of the cyclic depsipeptide YM-280193, a platelet aggregation inhibitor. *Organic Letters*, **2015**, 17, 492-5	6.2	28
123	Lipid: Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes. *Contemporary Diabetes*, **2014**, 215-229	0	
122	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. *Contemporary Diabetes*, **2014**, 435-453	0	

121	Platelet-derived growth factor-stimulated versican synthesis but not glycosaminoglycan elongation in vascular smooth muscle is mediated via Akt phosphorylation. *Cellular Signalling*, **2014**, 26, 912-6	4.9	10
120	Transforming growth factor -mediated site-specific Smad linker region phosphorylation in vascular endothelial cells. *Journal of Pharmacy and Pharmacology*, **2014**, 66, 1722-33	4.8	24
119	Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle. *Cardiovascular Diabetology*, **2014**, 13, 80	8.7	7
118	The nerve growth factor signaling and its potential as therapeutic target for glaucoma. *BioMed Research International*, **2014**, 2014, 759473	3	51
117	Fixed-dose statins with no lipid targets: a new paradigm of dosing?. *Journal of Pharmacy Practice and Research*, **2014**, 44, 64-65	0.7	
116	Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications. *Medicinal Research Reviews*, **2014**, 34, 644-75	14.4	66
115	Stereoselective reduction of 1-o-isopropyloxygenipin enhances its neuroprotective activity in neuronal cells from apoptosis induced by sodium nitroprusside. *ChemMedChem*, **2014**, 9, 1397-401	3.7	8
114	Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. *Journal of Lipid Research*, **2014**, 55, 201-13	6.3	67
113	Transforming growth factor- signalling: role and consequences of Smad linker region phosphorylation. *Cellular Signalling*, **2013**, 25, 2017-24	4.9	190
112	Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans. *Cardiovascular Pathology*, **2013**, 22, 146-55	3.8	19
111	LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. *Cellular and Molecular Life Sciences*, **2013**, 70, 2859-72	10.3	195
110	GPCR responses in vascular smooth muscle can occur predominantly through dual transactivation of kinase receptors and not classical G protein signalling pathways. *Life Sciences*, **2013**, 92, 951-6	6.8	16
109	Thrombin-mediated proteoglycan synthesis utilizes both protein-tyrosine kinase and serine/threonine kinase receptor transactivation in vascular smooth muscle cells. *Journal of Biological Chemistry*, **2013**, 288, 7410-9	5.4	37
108	Siah2-deficient mice show impaired skin wound repair. *Wound Repair and Regeneration*, **2013**, 21, 437-47	3.6	5
107	Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells. *Journal of Pharmacy and Pharmacology*, **2013**, 65, 1055-63	4.8	13
106	Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors. *Journal of Pharmacy and Pharmacology*, **2013**, 65, 465-73	4.8	20
105	(S)-[6]-Gingerol inhibits TGF- stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells. *Journal of Pharmacy and Pharmacology*, **2013**, 65, 1026-36	4.8	31
104	Cell biology of Smad2/3 linker region phosphorylation in vascular smooth muscle. *Clinical and Experimental Pharmacology and Physiology*, **2012**, 39, 661-7	3	27

103	Cardiovascular actions and therapeutic potential of tanshinone IIA. *Atherosclerosis*, **2012**, 220, 3-10	3.1	249
102	Corrigendum to: Cardiovascular actions and therapeutic potential of tanshinone IIA [Atherosclerosis 220 (2012) 3□10]. *Atherosclerosis*, **2012**, 221, 604	3.1	4
101	Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-B activation. *Translational Research*, **2012**, 160, 114-24	11	68
100	Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGF□receptor phosphorylation. *Archives of Biochemistry and Biophysics*, **2012**, 525, 25-31	4.1	13
99	Insulin-like growth factor-1 induces the phosphorylation of PRAS40 via the PI3K/Akt signaling pathway in PC12 cells. *Neuroscience Letters*, **2012**, 516, 105-9	3.3	20
98	G protein coupled receptor transactivation: extending the paradigm to include serine/threonine kinase receptors. *International Journal of Biochemistry and Cell Biology*, **2012**, 44, 722-7	5.6	25
97	The possible role of the Akt signaling pathway in schizophrenia. *Brain Research*, **2012**, 1470, 145-58	3.7	81
96	Forkhead family transcription factor FoxO and neural differentiation. *Neurogenetics*, **2012**, 13, 105-13	3	21
95	Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. *Archives of Biochemistry and Biophysics*, **2011**, 515, 72-9	4.1	67
94	Characterization of intracellular translocation of Forkhead transcription factor O (FoxO) members induced by NGF in PC12 cells. *Neuroscience Letters*, **2011**, 498, 31-6	3.3	24
93	The paradigm of G protein receptor transactivation: a mechanistic definition and novel example. *Scientific World Journal, The*, **2011**, 11, 709-14	2.2	22
92	Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. *Pharmacology & Therapeutics*, **2011**, 131, 255-68	13.9	58
91	Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. *Cellular and Molecular Life Sciences*, **2011**, 68, 97-107	10.3	55
90	TGF-stimulates biglycan core protein synthesis but not glycosaminoglycan chain elongation via Akt phosphorylation in vascular smooth muscle. *Growth Factors*, **2011**, 29, 203-10	1.6	21
89	Transforming growth factor-regulation of proteoglycan synthesis in vascular smooth muscle: contribution to lipid binding and accelerated atherosclerosis in diabetes. *Journal of Diabetes*, **2010**, 2, 233-42	3.8	46
88	Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor. *Journal of Biological Chemistry*, **2010**, 285, 26798-26805	5.4	56
87	Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways. *Journal of Biological Chemistry*, **2010**, 285, 6987-95	5.4	23
86	PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL. *Endocrinology*, **2010**, 151, 4356-67	4.8	47

85	Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. *Journal of Cellular and Molecular Medicine*, **2010**, 14, 1408-18	5.6	53
84	Endothelin-1 stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by endothelin receptor transactivation of the transforming growth factor-[beta] type I receptor. *Journal of Cardiovascular Pharmacology*, **2010**, 56, 360-8	3.1	41
83	TGF-beta stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2. *Cellular and Molecular Life Sciences*, **2010**, 67, 2077-90	10.3	70
82	Zinc and cardiovascular disease. *Nutrition*, **2010**, 26, 1050-7	4.8	128
81	Characterisation of Ki11502 as a potent inhibitor of PDGF beta receptor-mediated proteoglycan synthesis in vascular smooth muscle cells. *European Journal of Pharmacology*, **2010**, 626, 186-92	5.3	10
80	Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes. *Scientific World Journal, The*, **2009**, 9, 224-8	2.2	15
79	Growth factor-mediated hyper-elongation of glycosaminoglycan chains on biglycan requires transcription and translation. *Archives of Physiology and Biochemistry*, **2009**, 115, 147-54	2.2	17
78	Factors affecting proteoglycan synthesis and structure that modify the interaction with lipoproteins. *Clinical Lipidology*, **2009**, 4, 479-492		4
77	Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteoglycans with increased binding to LDL. *Atherosclerosis*, **2009**, 205, 451-7	3.1	27
76	Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways. *Thrombosis Research*, **2008**, 123, 288-97	8.2	47
75	Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. *Atherosclerosis*, **2008**, 199, 237-47	3.1	109
74	The effect of PPAR ligands to modulate glucose metabolism alters the incorporation of metabolic precursors into proteoglycans synthesized by human vascular smooth muscle cells. *Archives of Physiology and Biochemistry*, **2008**, 114, 171-7	2.2	5
73	Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle. *Journal of Biological Chemistry*, **2008**, 283, 7844-52	5.4	48
72	Phosphorylated troglitazone activates PPARgamma and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis. *Journal of Cardiovascular Pharmacology*, **2008**, 51, 274-9	3.1	9
71	Glucosamine inhibits the synthesis of glycosaminoglycan chains on vascular smooth muscle cell proteoglycans by depletion of ATP. *Archives of Physiology and Biochemistry*, **2008**, 114, 120-6	2.2	12
70	p38 MAP kinase mediated proteoglycan synthesis as a target for the prevention of atherosclerosis. *Cardiovascular & Hematological Disorders Drug Targets*, **2008**, 8, 287-92	1.1	10
69	Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. *Current Vascular Pharmacology*, **2008**, 6, 195-203	3.3	36
68	Calcific Aortic Valve Disease and Hypertension. *Current Hypertension Reviews*, **2008**, 4, 107-113	2.3	

67	Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding. *Journal of Cardiovascular Pharmacology*, **2008**, 52, 403-12	3.1	5
66	Another piece of cell biology in the puzzle of inflammation, glucose and diabetic vascular disease. *Journal of Hypertension*, **2008**, 26, 396-8	1.9	1
65	Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. *Current Opinion in Lipidology* , **2008**, 19, 448-54	4.4	71
64	Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process. *The Open Biochemistry Journal*, **2008**, 2, 135-42	0.9	33
63	Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. *Cardiovascular Diabetology*, **2007**, 6, 33	8.7	11
62	Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. *Journal of Diabetes and Its Complications*, **2007**, 21, 108-17	3.2	24
61	Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease. *Cardiovascular Research*, **2007**, 76, 19-28	9.9	44
60	Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. *Vascular Health and Risk Management*, **2007**, 3, 117-24	4.4	37
59	Insulin resistance and atherosclerosis. *Endocrine Reviews*, **2006**, 27, 242-59	27.2	241
58	Clinical thiazolidinediones as PPARgamma ligands with the potential for the prevention of cardiovascular disease in diabetes. *Current Diabetes Reviews*, **2006**, 2, 227-39	2.7	3
57	Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries. *Diabetes Research and Clinical Practice*, **2005**, 70, 201-8	7.4	7
56	Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. *Kidney International*, **2005**, 68, 2756-65	9.9	18
55	New approaches to regulating the chondroitin/dermatan sulfate glycosaminoglycan component of the vascular extracellular matrix. *Scientific World Journal, The*, **2005**, 5, 515-20	2.2	1
54	Androgens: new effects on proteoglycan biosynthesis and its consequences for atherosclerosis. *Scientific World Journal, The*, **2005**, 5, 521-6	2.2	1
53	Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands. *Current Cardiology Reviews*, **2005**, 1, 89-102	2.4	2
52	Androgens stimulate human vascular smooth muscle cell proteoglycan biosynthesis and increase lipoprotein binding. *Endocrinology*, **2005**, 146, 2085-90	4.8	26
51	Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis. *Vascular Health and Risk Management*, **2005**, 1, 199-208	4.4	13
50	Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. *Circulation*, **2003**, 107, 2548-50	16.7	83

49	Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 762-8	9.4	31
48	Impact of sleep apnea on sympathetic nervous system activity in heart failure. *Chest*, **2003**, 123, 1119-26	5.3	88
47	High glucose potentiates mitogenic responses of cultured ovine coronary smooth muscle cells to platelet derived growth factor and transforming growth factor-beta1. *Diabetes Research and Clinical Practice*, **2003**, 59, 93-101	7.4	13
46	Role of Na-H Exchanger in Vascular Remodelling in Diabetes **2003**, 159-175		1
45	High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells. *American Journal of Physiology - Endocrinology and Metabolism*, **2002**, 282, E746-51	6	13
44	Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 55-60	9.4	127
43	Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. *Atherosclerosis*, **2002**, 162, 119-29	3.1	57
42	Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. *Journal of Lipid Research*, **2002**, 43, 149-157	6.3	35
41	Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. *Journal of Lipid Research*, **2002**, 43, 149-57	6.3	31
40	Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. *Journal of Diabetes and Its Complications*, **2001**, 15, 120-7	3.2	35
39	Mechanical strain stimulates a mitogenic response in coronary vascular smooth muscle cells via release of basic fibroblast growth factor. *American Journal of Hypertension*, **2001**, 14, 1128-34	2.3	20
38	Effect of moderate alcohol upon obstructive sleep apnoea. *European Respiratory Journal*, **2000**, 16, 909-13	13.6	98
37	Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+) exchange and prevented by Na(+)-H(+) exchange inhibition. *Circulation Research*, **2000**, 87, 1133-40	15.7	55
36	Rapid regulation of adrenomedullin in metabolically compromised vascular smooth muscle cells. *Journal of Hypertension*, **1999**, 17, 373-9	1.9	9
35	Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes. *Biochemistry and Cell Biology*, **1998**, 76, 751-759	3.6	17
34	Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes. *Biochemistry and Cell Biology*, **1998**, 76, 751-9	3.6	5
33	Protection of neuronal uptake-1 inhibitors in ischemic and anoxic hearts by norepinephrine-dependent and -independent mechanisms. *Journal of Cardiovascular Pharmacology*, **1998**, 32, 621-8	3.1	18
32	Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain. *FEBS Letters*, **1997**, 414, 471-4	3.8	34

31	Role of Ca2+ in metabolic inhibition-induced norepinephrine release in rat brain synaptosomes. *Circulation Research*, **1997**, 80, 179-88	15.7	11
30	UNDEREXPRESSION OF THE 43 KDA INOSITOL POLY-PHOSPHATE 5-PHOSPHATASE IS ASSOCIATED WITH CELLULAR TRANSFORMATION. *Biochemical Society Transactions*, **1996**, 24, 624S-624S	5.1	
29	Regulation and role of urokinase plasminogen activator in vascular remodelling. *Clinical and Experimental Pharmacology and Physiology*, **1996**, 23, 759-65	3	44
28	Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme. *Clinical and Experimental Pharmacology and Physiology*, **1996**, 23, 549-51	3	30
27	Genetic and physiological association of diabetes susceptibility with raised Na+/H+ exchange activity. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 5898-902	11.5	72
26	Leu143 in the putative fourth membrane spanning domain is critical for amiloride inhibition of an epithelial Na+/H+ exchanger isoform (NHE-2). *Biochemical and Biophysical Research Communications*, **1993**, 193, 532-9	3.4	43
25	Dihydropyridine Ca2+ channel antagonists inhibit the salvage pathway for DNA synthesis in human vascular smooth muscle cells. *European Journal of Pharmacology*, **1993**, 244, 269-75		11
24	Endothelin-1 and endothelin-3 stimulate calcium mobilization by different mechanisms in vascular smooth muscle. *Biochemical and Biophysical Research Communications*, **1992**, 183, 694-700	3.4	41
23	Ionic mechanisms regulating sodium entry into vascular smooth muscle. *Clinical and Experimental Pharmacology and Physiology*, **1991**, 18, 117-20	3	4
22	Multiple growth abnormalities in vascular smooth muscle from spontaneously hypertensive rats. *Clinical and Experimental Pharmacology and Physiology*, **1991**, 18, 319-22	3	6
21	Primary "brown pigment" bile duct stones. *HPB Surgery*, **1991**, 4, 209-20; discussion 221-2		7
20	Mechanisms involved in the stimulation of aldosterone production by angiotensin II, vasopressin and endothelin. *Clinical and Experimental Pharmacology and Physiology*, **1990**, 17, 263-7	3	15
19	Sodium-dependent, ethylisopropylamiloride-sensitive mechanisms regulate intracellular pH in human vascular smooth muscle. *Clinical and Experimental Pharmacology and Physiology*, **1990**, 17, 297-301	3	4
18	Intracellular pH in human arterial smooth muscle. Regulation by Na+/H+ exchange and a novel 5-(N-ethyl-N-isopropyl)amiloride-sensitive Na(+)- and HCO3(-)-dependent mechanism. *Circulation Research*, **1990**, 67, 814-25	15.7	76
17	Angiotensin II and noradrenaline increase PDGF-BB receptors and potentiate PDGF-BB stimulated DNA synthesis in vascular smooth muscle. *Biochemical and Biophysical Research Communications*, **1990**, 166, 580-8	3.4	63
16	The pH of spontaneously beating cultured rat heart cells is regulated by an ATP-calmodulin-dependent Na+/H+ antiport. *Circulation Research*, **1989**, 64, 676-85	15.7	68
15	Spontaneous oscillations in cytoplasmic free calcium concentration in vascular smooth muscle: a potential mechanism associated with myogenic tone. *Clinical and Experimental Pharmacology and Physiology*, **1988**, 15, 281-4	3	4
14	Amiloride analogues cause endothelium-dependent relaxation in the canine coronary artery in vitro: possible role of Na+/Ca2+ exchange. *British Journal of Pharmacology*, **1988**, 95, 67-76	8.6	20

13	Circulating digoxin-like immunoreactivity in renal hypertensive rabbits: lack of modulation by alterations in dietary sodium intake. *Journal of Hypertension*, **1988**, 6, 205-9	1.9	5
12	Regulation of sodium influx and sodium, potassium pump activity by a sodium-hydrogen antiport in rat vascular smooth muscle. *Clinical and Experimental Pharmacology and Physiology*, **1987**, 14, 191-5	3	5
11	Temperature-dependent disposition of [14C]benzo(a)pyrene in the spiny lobster, Panulirus argus. *Toxicology and Applied Pharmacology*, **1985**, 77, 325-33	4.6	34
10	Effects of alterations in cell phenotype and hypokalemia on sodium-potassium pump activity in rabbit vascular smooth muscle. *Clinical and Experimental Hypertension*, **1985**, 7, 1563-82		2
9	Desensitization of the alpha 1 adrenoceptor system in vascular smooth muscle. *Biochemical Pharmacology*, **1984**, 33, 1143-5	6	26
8	Plasma noradrenaline kinetics in humans. *Journal of the Autonomic Nervous System*, **1984**, 11, 125-44		76
7	3-Methylcholanthrene does not induce in vitro xenobiotic metabolism in spiny lobster hepatopancreas, or affect in vivo disposition of benzo[a]pyrene. *Comparative Biochemistry and Physiology Part C: Comparative Pharmacology*, **1984**, 78, 241-5		7
6	Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships. *Journal of Medicinal Chemistry*, **1982**, 25, 887-92	8.3	53
5	Inhibitors of hepatic mixed function oxidases--V. Inhibition of aminopyrine N-demethylation and enhancement of aniline hydroxylation by benzoxazole derivatives. *Biochemical Pharmacology*, **1982**, 31, 1795-8	6	5
4	Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats. *Journal of Medicinal Chemistry*, **1982**, 25, 622-6	8.3	25
3	Imidazole derivatives as inhibitors of cytochrome P-450-dependent oxidation and activators of epoxide hydrolase in hepatic microsomes from a marine fish. *Biochemical Pharmacology*, **1981**, 30, 2876-80	6	11
2	Polyhalogenated biphenyls and phenobarbital: evaluation as inducers of drug metabolizing enzymes in the sheepshead, Archosargus probatocephalus. *Chemico-Biological Interactions*, **1981**, 36, 229-48	5	52
1	Inhibitors of hepatic mixed function oxidases--II. Some benzimidazole, benzoxazole and benzothiazole derivatives. *Biochemical Pharmacology*, **1976**, 25, 2747-50	6	40